IMNM

Put Contract Overview: The $13.00 put contract for IMNM has a bid of $1.50, allowing investors to buy shares at an effective cost of $11.50, which is a 13% discount from the current price of $14.96. There is a 76% chance the contract may expire worthless, offering an 11.54% return on cash commitment.

Call Contract Overview: The $17.00 call contract has a bid of $3.50, and if shares are purchased at $14.96 and the call is sold, it could yield a total return of 37.03% if exercised by December 2026. There is a 32% chance this contract may also expire worthless, providing a potential 23.40% additional return.

Volatility Insights: The implied volatility for the put contract is 95%, while for the call contract it is 101%. The actual trailing twelve-month volatility is calculated at 78%, indicating significant price movement expectations.

YieldBoost Concept: Both the put and call contracts offer a "YieldBoost," with the put providing a 10.37% annualized return if it expires worthless, and the call offering a 21.03% annualized return under similar conditions.

Company Presentation: Immunome, Inc. will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 11, 2025, at 8:30 a.m. ET, with a live audio webcast available on their website.

Company Overview: Immunome is a clinical-stage biotechnology company focused on developing targeted cancer therapies, including antibody-drug conjugates (ADCs), to improve patient outcomes.

Pipeline Highlights: The company's advanced pipeline includes varegacestat in a Phase 3 trial for desmoid tumors, IM-1021 in a Phase 1 trial, and IM-3050, which has received IND clearance.

Additional Programs: Immunome's pipeline also features several preclinical ADCs (IM-1617, IM-1335, IM-1340) targeting undisclosed markers in multiple solid tumors.

Immunome's New ADC Payload: Immunome, Inc. presented preclinical data on its antibody-drug conjugate (ADC) payload HC74, which effectively overcomes multiple resistance mechanisms associated with ADCs, such as drug efflux and target heterogeneity.

Clinical Trials and Efficacy: HC74, a topoisomerase I inhibitor, is being used in the ROR1-targeted ADC IM-1021, currently in Phase 1 trials, and has shown significant efficacy in preclinical models of various cancers, including colorectal and non-small cell lung cancer.

Company's Commitment to Innovation: Immunome is focused on developing first-in-class and best-in-class targeted cancer therapies, with a diverse pipeline that includes several ADCs and other innovative treatments aimed at improving cancer patient outcomes.

Forward-Looking Statements: The company issued cautionary statements regarding forward-looking statements, highlighting the uncertainties and risks associated with the development and regulatory approval of its product candidates.